Malaria remains one of the most significant infectious diseases affecting populations in tropical and subtropical regions. The disease continues to create substantial healthcare burdens, particularly across sub-Saharan Africa and other endemic areas. Growing efforts toward prevention, diagnosis, vaccination, and effective treatment are reshaping the global healthcare landscape.

The Malaria Treatment Market was valued at approximately US$3.30 billion in 2022 and is projected to reach US$24.49 billion by 2030, expanding at a CAGR of 28.5% from 2022 to 2030. The strong growth outlook is associated with the high prevalence of malaria, increasing government and international elimination initiatives, advances in diagnostic technologies, and rising research and development activities for improved therapeutics and vaccines. The increasing burden of Plasmodium falciparum and Plasmodium vivax infections further supports demand for effective antimalarial interventions.

Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00018229

Rising Malaria Burden Drives Demand for Effective Treatment

Malaria is caused by Plasmodium parasites and is primarily transmitted through infected female Anopheles mosquitoes. Among the five parasite species known to infect humans, P. falciparum and P. vivax represent major public health concerns. P. falciparum is particularly prevalent in Africa and is associated with severe and potentially fatal disease, while P. vivax remains widespread outside sub-Saharan Africa.

The burden of malaria became more challenging during the COVID-19 pandemic because disruptions to healthcare services affected diagnosis, prevention, and treatment programs. According to the reference data, more than 13 million malaria cases and approximately 63,000 associated deaths were linked to disruptions during the two peak pandemic years. In 2021, the WHO African Region accounted for approximately 95% of global malaria cases and 96% of malaria deaths, highlighting the significant unmet need for treatment and disease-control solutions.

Vaccines and Innovative Therapeutics Strengthen Growth Prospects

Treatment segmentation includes generic drugs, originators, vaccines, and other therapies. Vaccines represented the largest segment in 2022 and are expected to record the highest CAGR during the forecast period. Increasing investments in vaccine development and the expansion of immunization programs are supporting this trend.

The RTS,S malaria vaccine developed by GSK has played an important role in advancing malaria prevention. The vaccine targets P. falciparum and has been introduced through national immunization programs in sub-Saharan African countries. In parallel, pharmaceutical companies and research organizations are advancing new vaccine candidates and therapeutic compounds designed to improve efficacy, simplify dosing, and address drug resistance.

Antimalarial combination therapies also remain important. Artemisinin-based combination therapies are widely used for uncomplicated P. falciparum malaria and remain among the most effective available treatment options. Pipeline development involving compounds with longer half-lives and potential single-dose regimens could further transform treatment accessibility and patient adherence.

Oral Administration Leads While Parenteral Therapies Gain Momentum

By route of administration, the market is divided into oral and parenteral therapies. Oral administration held the larger share in 2022 because of its convenience, cost-effectiveness, ease of manufacturing, and favorable patient compliance. Tablets and capsules are particularly suitable for widespread distribution in resource-constrained settings.

Common antimalarial medicines include quinine, quinidine, chloroquine, amodiaquine, tafenoquine, proguanil, chlorproguanil, and artemisinin-based therapies. However, the parenteral segment is expected to experience a higher CAGR during the forecast period. Injectable therapies are particularly important for severe malaria cases in which patients require rapid treatment or cannot take oral medicines.

Direct Tenders and Regional Programs Support Distribution

The distribution channel landscape comprises direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Direct tenders accounted for the largest share in 2022 and are expected to register the highest CAGR through 2030. Government procurement programs and large-scale healthcare initiatives depend heavily on tender-based purchasing to secure medicines and diagnostic products at scale.

The Middle East & Africa region held the largest share in 2022, reflecting the exceptionally high disease burden across African countries. Nigeria represents a major country-level contributor, with approximately 97% of its population considered at high risk of malaria. National initiatives, including the High Burden High Impact approach implemented with WHO technical support, are strengthening efforts to improve prevention, diagnosis, and treatment.

Competitive Landscape and Strategic Developments

The competitive environment is characterized by pharmaceutical companies, vaccine developers, generic drug manufacturers, and specialized research organizations. Key players include:

• GSK Plc
• Novartis AG
• Cipla Ltd
• Sun Pharmaceutical Industries Ltd
• Sanofi SA
• Viatris Inc
• Lupin Ltd
• Zydus Group
• VLP Therapeutics LLC
• AdvaCare Pharma USA LLC

Strategic collaborations, product development, regulatory approvals, and R&D investments are central to competitive positioning. For instance, tafenoquine was licensed in Australia in 2022 for children and adolescents in combination with chloroquine. Zydus also advanced development of ZY19489, an investigational antimalarial compound that demonstrated potential for single-dose treatment in early studies. Such developments indicate a broader industry focus on improving treatment efficacy, adherence, and accessibility.

Future Outlook

Continued malaria elimination programs, expanding vaccination initiatives, innovations in antimalarial drugs, and improvements in healthcare access are expected to create substantial opportunities. However, drug resistance and counterfeit medicines remain significant challenges. Continued collaboration among governments, pharmaceutical companies, international organizations, and research institutions will be essential for developing affordable, effective, and accessible solutions capable of reducing the global malaria burden.

Related Report:

1) Pulp and Root Repair Market Size, Share, and Analysis by 2027

2) Medical Audiometer Devices Market Dynamics and Trends by 2028

3) Radiation Protection Apron Market Analysis, Size, and Share by 2030

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish